P3I
ASND icon

Progeny 3 Inc’s Ascendis Pharma A/S ASND Stock Holding History

Progeny 3 Inc’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Hold
5,230
– – 0.07% 29
2026
Q1 		$1.2M Hold
5,230
– – 0.06% 31
2025
Q4 		$1.12M Buy
+5,230
New +$1.08M 0.06% 35

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Progeny 3 Inc's ASND Position: Q2 2026 in Review

Progeny 3 Inc held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 5,230 shares worth $1.39M. The position accounts for 0.07% of the portfolio, ranked #29.

Progeny 3 Inc first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Progeny 3 Inc held 5,230 shares of Ascendis Pharma A/S worth $1.39M as of Q2 2026.
  • Progeny 3 Inc left its Ascendis Pharma A/S share count unchanged in Q2 2026.
  • Ascendis Pharma A/S made up 0.07% of Progeny 3 Inc's portfolio in Q2 2026, its #29 holding.
  • Progeny 3 Inc first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Progeny 3 Inc's 13F filing for Q2 2026, filed 14 Aug 2026.